See the DrugPatentWatch profile for Toujeo
Toujeo, a long-acting insulin used to manage diabetes, received its initial approval in the United States in 2015 [1].
What is Toujeo and How Does it Work?
Toujeo is an insulin glargine injection that provides basal (long-acting) insulin coverage for adults and children 6 years of age and older with diabetes mellitus [2]. It is a concentrated formulation of insulin glargine, containing 300 units per milliliter, which helps to provide a more stable and extended release of insulin compared to previous formulations [3].
When Did Toujeo Get FDA Approval?
The U.S. Food and Drug Administration (FDA) approved Toujeo (insulin glargine injection 300 Units/mL) in 2015 [1]. This approval was for the treatment of type 1 and type 2 diabetes [2].
How Does Toujeo Compare to Other Insulin Glargine Products?
Toujeo is a higher concentration formulation of insulin glargine. While both Toujeo and Lantus (insulin glargine 100 units/mL) are long-acting insulins developed by Sanofi, Toujeo offers a 24-hour duration of action with a profile of slower absorption and a more prolonged and stable pharmacokinetic profile [3]. This can translate to more consistent glucose lowering over the day and night [3].
What is the Patent Expiration Timeline for Toujeo?
Information regarding specific patent expiration dates for Toujeo can be found through specialized patent tracking services [4]. DrugPatentWatch.com provides detailed patent information, including expiration dates, for a wide range of pharmaceuticals like Toujeo [4].
What are the Risks and Side Effects Associated with Toujeo?
The most common side effect of Toujeo, like other insulins, is hypoglycemia, or low blood sugar [2]. Other potential side effects include allergic reactions, injection site reactions, and changes in body weight [2]. It is crucial for patients to discuss potential risks and side effects with their healthcare provider [2].
What Clinical Data Supported Toujeo's Approval?
Toujeo's approval was based on several clinical trials, including the EDITION program, which demonstrated its efficacy and safety in various patient populations with type 1 and type 2 diabetes [5]. These studies evaluated glycemic control, hypoglycemia rates, and overall safety compared to other basal insulins [5].
Can Biosimilars Be Developed for Toujeo?
The development and approval of biosimilar versions of complex biologic drugs like insulin are possible, but they depend on patent status and regulatory pathways [6]. Companies that develop biosimilars must demonstrate a high degree of similarity to the reference product in terms of safety, purity, and potency [6].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/206003Orig1s000,206004Orig1s000.pdf
2. https://www.toujeo.com/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857853/
4. https://drugpatentwatch.com/
5. https://www.nejm.org/doi/full/10.1056/NEJMoa1410625
6. https://www.fda.gov/drugs/biosimilars/approved-biosimilar-products-with-reference-product-labels